We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 02, 2019

Ramucirumab + Docetaxel vs Placebo + Docetaxel in Advanced Urothelial Carcinoma After Platinum-Based Therapy

The Lancet Oncology


Additional Info

The Lancet Oncology
Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Platinum-Based Therapy (RANGE): Overall Survival and Updated Results of a Randomised, Double-Blind, Phase 3 Trial
Lancet Oncol 2019 Nov 18;[EPub Ahead of Print], DP Petrylak, R de Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, D Castellano, SA Hussain, A Fléchon, A Bamias, EY Yu, MS van der Heijden, N Matsubara, B Alekseev, A Necchi, L Géczi, YC Ou, HS Coskun, WP Su, J Bedke, G Gakis, IJ Percent, JL Lee, M Tucci, A Semenov, F Laestadius, A Peer, G Tortora, S Safina, X Garcia Del Muro, A Rodriguez-Vida, I Cicin, H Harputluoglu, ST Tagawa, U Vaishampayan, JB Aragon-Ching, O Hamid, AM Liepa, S Wijayawardana, F Russo, RA Walgren, AH Zimmermann, RR Hozak, KM Bell-McGuinn, T Powles

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.